Figure 5.

Plasma S100A9 levels in MPN. (a) Plasma S100A9 was measured in 58 patients with MPN (including 22 ET, 17 PV, 19 MF (4-ETMF, one 4-PVMF, and 11 PMF) and 10 controls. The S100 A9 results (ng/ml) were ET (20.57 ± 3.47) (n = 22), PV (33.20 ± 2.98) (n = 17), MF (42.02 ± 2.42) (n = 19), MPN (31.30 ± 2.11) (n = 58), and controls (22.17 ± 2.45) (n = 19). Plasma S100A9 was significantly elevated in PV (P  < 0.01), MF (P  < 0.0001), and MPN (P  < 0.05) compared with controls. MF was not significantly from PV but was significantly elevated relative to ET. PV was significantly elevated compared to ET, but the ET group was not different from the controls. (b) Jak2 mutant and CALR mutant patients also were found to have significantly increased than controls with mean ± SE of than controls (P  < 0.001), and CALR mutant patients were of 36.9 ± 1.7 (P  < 0.001) and 33.6 ± 2.5 (P=0.01) as compared to controls (22.5 ± 2.3), while there was no difference between JAK2 mutant and CALR mutant patients. (c) ROS in MPN. ROS was measured by flow cytometry in 44 patients with MPN, 15 MF (two patients with post-PV-MF, one with post-ET-MF, 13 patients with PMF), 18 patients with ET, and 11 patients with PV. The results (MFI, mean ± SE) show that ROS was elevated in the MF (2,127 ± 261.6, n = 15) group relative to the PV (1,090 ± 163.8, n = 11), ET (1,031 ± 140.9, n = 18), and controls (549.1 ± 52.50) (n = 9). MF was significantly elevated than PV or ET (P  < 0.01) and controls (P  < 0.001), while PV and ET were not significantly different from controls.